Literature DB >> 27222277

Inverse psoriasis treated with ustekinumab.

Manuel António Campos1, Paulo Varela1, Armando Baptista1, Ana Isabel Moreira1.   

Abstract

Inverse psoriasis is characterised by the involvement of flexural skin folds. This form of psoriasis has distinct clinical and therapeutic features. This report refers to the case of a 48-year-old Caucasian man who was observed in our department, with a clinically and biopsy proven diagnosis of inverse psoriasis. For 2 years, the patient was treated with different combinations of corticosteroids, vitamin D analogues and methotrexate, with no satisfactory response. Given the lack of a clinical response and comorbidities, latent tuberculosis was excluded, and we started treatment with ustekinumab. We chose this biological agent because the patient was a long-distance truck driver and refused the possibility of autoinjections. The patient underwent three ustekinumab injections, which resulted in significant improvement of pruritus, erythaematous lesions and quality of life. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27222277      PMCID: PMC4885339          DOI: 10.1136/bcr-2016-215019

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  Clinical analysis of 48 cases of inverse psoriasis: a hospital-based study.

Authors:  Gang Wang; Chunying Li; Tianwen Gao; Yufeng Liu
Journal:  Eur J Dermatol       Date:  2005 May-Jun       Impact factor: 3.328

Review 2.  Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris?

Authors:  Silje Haukali Omland; Robert Gniadecki
Journal:  Clin Dermatol       Date:  2015-04-08       Impact factor: 3.541

3.  The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients.

Authors:  Nihal Kundakci; Umit Türsen; Muhammed O A Babiker; Erbak Gürgey
Journal:  Int J Dermatol       Date:  2002-04       Impact factor: 2.736

4.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Authors:  Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

  4 in total
  5 in total

1.  Combination Therapy of Tacrolimus and Chinese Herb Medicated Bath in Children with Inverse Psoriasis.

Authors:  Min-Feng Wu; Su Li; Yong-Mei Qian; Xin Li; Yu Chen; Ruo-Yi Wei; Bin Li; Fu-Lun Li
Journal:  Chin J Integr Med       Date:  2017-09-15       Impact factor: 1.978

Review 2.  [Intertriginous psoriasis].

Authors:  C Thomas; M Matthies; B Homey; S Meller
Journal:  Hautarzt       Date:  2020-04       Impact factor: 0.751

Review 3.  Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis.

Authors:  Nilendu Sarma
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

Review 4.  Psoriasis and Metabolic Syndrome: Comorbidities and Environmental and Therapeutic Implications.

Authors:  Cesar Peralta; Pousette Hamid; Humera Batool; Zeina Al Achkar; Pierre Maximus
Journal:  Cureus       Date:  2019-12-12

Review 5.  Inverse Psoriasis: From Diagnosis to Current Treatment Options.

Authors:  Giuseppe Micali; Anna Elisa Verzì; Giorgia Giuffrida; Enrico Panebianco; Maria Letizia Musumeci; Francesco Lacarrubba
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.